



Potent Agent Research for Glioblastoma Treatment

Guest Editor:

**Prof. Dr. Athanassios P.
Kyritsis**

Neurosurgical Institute, Medical
School, University of Ioannina,
45500 Ioannina, Greece

Deadline for manuscript
submissions:

closed (15 June 2022)

Message from the Guest Editor

Dear Colleagues,

Glioblastoma multiforme is one of the most resistant malignant tumors to any therapeutic modality. The survival of patients with this tumor is just over 12 months, even with an aggressive combination of surgery, radiotherapy, and chemotherapy. Most obstacles to its treatment consist of the protective sanctuary that the blood–brain barrier offers to it and its diffuse and infiltrating nature, given the specific organization of the brain with long and interconnecting cells through relatively long distances. The aim of this Special Issue is to compile and report new challenging research that aims toward the development of new techniques or therapies that can be used either for the most complete resection of the tumor during surgery, development of more effective radiosensitizers, or more effective chemotherapies or biologic therapies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI